Logo image of HITI

HIGH TIDE INC (HITI) Stock Fundamental Analysis

NASDAQ:HITI - Nasdaq - CA42981E4013 - Common Stock

3.01  +0.01 (+0.33%)

Premarket: 3.05 +0.04 (+1.33%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to HITI. HITI was compared to 195 industry peers in the Pharmaceuticals industry. HITI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HITI has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

HITI had positive earnings in the past year.
In the past year HITI had a positive cash flow from operations.
HITI had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: HITI reported negative operating cash flow in multiple years.
HITI Yearly Net Income VS EBIT VS OCF VS FCFHITI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M

1.2 Ratios

The Return On Assets of HITI (-12.76%) is better than 69.35% of its industry peers.
With a decent Return On Equity value of -20.98%, HITI is doing good in the industry, outperforming 70.97% of the companies in the same industry.
HITI has a better Return On Invested Capital (5.23%) than 82.26% of its industry peers.
Industry RankSector Rank
ROA -12.76%
ROE -20.98%
ROIC 5.23%
ROA(3y)-19.16%
ROA(5y)-26.31%
ROE(3y)-33.35%
ROE(5y)-88.22%
ROIC(3y)N/A
ROIC(5y)N/A
HITI Yearly ROA, ROE, ROICHITI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150 -200 -250

1.3 Margins

The Operating Margin of HITI (2.49%) is better than 77.96% of its industry peers.
HITI's Gross Margin of 27.34% is in line compared to the rest of the industry. HITI outperforms 51.61% of its industry peers.
HITI's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 2.49%
PM (TTM) N/A
GM 27.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.06%
GM growth 5Y-5.4%
HITI Yearly Profit, Operating, Gross MarginsHITI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 -60 -80

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), HITI is destroying value.
Compared to 1 year ago, HITI has more shares outstanding
HITI has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, HITI has a worse debt to assets ratio.
HITI Yearly Shares OutstandingHITI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
HITI Yearly Total Debt VS Total AssetsHITI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 3.45 indicates that HITI is not in any danger for bankruptcy at the moment.
HITI's Altman-Z score of 3.45 is fine compared to the rest of the industry. HITI outperforms 75.81% of its industry peers.
The Debt to FCF ratio of HITI is 2.59, which is a good value as it means it would take HITI, 2.59 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 2.59, HITI belongs to the best of the industry, outperforming 93.01% of the companies in the same industry.
A Debt/Equity ratio of 0.30 indicates that HITI is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.30, HITI is not doing good in the industry: 60.75% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF 2.59
Altman-Z 3.45
ROIC/WACC0.57
WACC9.19%
HITI Yearly LT Debt VS Equity VS FCFHITI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

HITI has a Current Ratio of 1.26. This is a normal value and indicates that HITI is financially healthy and should not expect problems in meeting its short term obligations.
HITI has a worse Current ratio (1.26) than 80.65% of its industry peers.
HITI has a Quick Ratio of 1.26. This is a bad value and indicates that HITI is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.78, HITI is not doing good in the industry: 86.02% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 0.78
HITI Yearly Current Assets VS Current LiabilitesHITI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

6

3. Growth

3.1 Past

HITI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 133.53%, which is quite impressive.
Looking at the last year, HITI shows a very negative growth in Revenue. The Revenue has decreased by -12.91% in the last year.
Measured over the past years, HITI shows a very strong growth in Revenue. The Revenue has been growing by 123.48% on average per year.
EPS 1Y (TTM)133.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
Revenue 1Y (TTM)-12.91%
Revenue growth 3Y80.26%
Revenue growth 5Y123.48%
Sales Q2Q%5.9%

3.2 Future

Based on estimates for the next years, HITI will show a very strong growth in Earnings Per Share. The EPS will grow by 69.57% on average per year.
The Revenue is expected to grow by 12.66% on average over the next years. This is quite good.
EPS Next Y83.17%
EPS Next 2Y66.9%
EPS Next 3Y71.34%
EPS Next 5Y69.57%
Revenue Next Year6.77%
Revenue Next 2Y10.34%
Revenue Next 3Y12.36%
Revenue Next 5Y12.66%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
HITI Yearly Revenue VS EstimatesHITI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
HITI Yearly EPS VS EstimatesHITI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 -1

5

4. Valuation

4.1 Price/Earnings Ratio

HITI is valuated quite expensively with a Price/Earnings ratio of 75.25.
Based on the Price/Earnings ratio, HITI is valued a bit cheaper than 79.03% of the companies in the same industry.
When comparing the Price/Earnings ratio of HITI to the average of the S&P500 Index (28.19), we can say HITI is valued expensively.
HITI is valuated quite expensively with a Price/Forward Earnings ratio of 91.55.
Compared to the rest of the industry, the Price/Forward Earnings ratio of HITI indicates a somewhat cheap valuation: HITI is cheaper than 73.12% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 24.37. HITI is valued rather expensively when compared to this.
Industry RankSector Rank
PE 75.25
Fwd PE 91.55
HITI Price Earnings VS Forward Price EarningsHITI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

HITI's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HITI is cheaper than 88.17% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, HITI is valued cheaper than 89.78% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.55
EV/EBITDA 8.79
HITI Per share dataHITI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HITI's earnings are expected to grow with 71.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.9
PEG (5Y)N/A
EPS Next 2Y66.9%
EPS Next 3Y71.34%

0

5. Dividend

5.1 Amount

No dividends for HITI!.
Industry RankSector Rank
Dividend Yield N/A

HIGH TIDE INC

NASDAQ:HITI (1/22/2025, 8:00:02 PM)

Premarket: 3.05 +0.04 (+1.33%)

3.01

+0.01 (+0.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-16 2024-09-16/amc
Earnings (Next)01-29 2025-01-29/amc
Inst Owners10.42%
Inst Owner Change0%
Ins Owners9.07%
Ins Owner ChangeN/A
Market Cap242.15M
Analysts82.5
Price Target4.34 (44.19%)
Short Float %5.86%
Short Ratio5.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)112.38%
Min EPS beat(2)85.15%
Max EPS beat(2)139.6%
EPS beat(4)4
Avg EPS beat(4)134.75%
Min EPS beat(4)85.15%
Max EPS beat(4)214.25%
EPS beat(8)8
Avg EPS beat(8)85.13%
EPS beat(12)11
Avg EPS beat(12)55.98%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.81%
Min Revenue beat(2)-3.51%
Max Revenue beat(2)1.9%
Revenue beat(4)2
Avg Revenue beat(4)-0.55%
Min Revenue beat(4)-3.51%
Max Revenue beat(4)1.9%
Revenue beat(8)6
Avg Revenue beat(8)1.94%
Revenue beat(12)10
Avg Revenue beat(12)9.68%
Revenue beat(16)13
Avg Revenue beat(16)7.6%
PT rev (1m)-5.54%
PT rev (3m)-6.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.65%
EPS NY rev (1m)0%
EPS NY rev (3m)71.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 75.25
Fwd PE 91.55
P/S 0.68
P/FCF 13.55
P/OCF 9.77
P/B 2.39
P/tB 7.27
EV/EBITDA 8.79
EPS(TTM)0.04
EY1.33%
EPS(NY)0.03
Fwd EY1.09%
FCF(TTM)0.22
FCFY7.38%
OCF(TTM)0.31
OCFY10.23%
SpS4.43
BVpS1.26
TBVpS0.41
PEG (NY)0.9
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.76%
ROE -20.98%
ROCE 7.12%
ROIC 5.23%
ROICexc 6.43%
ROICexgc 17.07%
OM 2.49%
PM (TTM) N/A
GM 27.34%
FCFM 5.01%
ROA(3y)-19.16%
ROA(5y)-26.31%
ROE(3y)-33.35%
ROE(5y)-88.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.06%
GM growth 5Y-5.4%
F-Score6
Asset Turnover2.14
Health
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF 2.59
Debt/EBITDA 1.06
Cap/Depr 34.64%
Cap/Sales 1.94%
Interest Coverage 250
Cash Conversion 85.99%
Profit Quality N/A
Current Ratio 1.26
Quick Ratio 0.78
Altman-Z 3.45
F-Score6
WACC9.19%
ROIC/WACC0.57
Cap/Depr(3y)31.35%
Cap/Depr(5y)175.52%
Cap/Sales(3y)3.23%
Cap/Sales(5y)9.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)133.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
EPS Next Y83.17%
EPS Next 2Y66.9%
EPS Next 3Y71.34%
EPS Next 5Y69.57%
Revenue 1Y (TTM)-12.91%
Revenue growth 3Y80.26%
Revenue growth 5Y123.48%
Sales Q2Q%5.9%
Revenue Next Year6.77%
Revenue Next 2Y10.34%
Revenue Next 3Y12.36%
Revenue Next 5Y12.66%
EBIT growth 1Y214.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year261.82%
EBIT Next 3Y64.87%
EBIT Next 5Y48.08%
FCF growth 1Y331.06%
FCF growth 3Y33.84%
FCF growth 5YN/A
OCF growth 1Y2777%
OCF growth 3Y32.66%
OCF growth 5YN/A